Compare Moderna, Inc. (MRNA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Schwab US Dividend Equity ETF — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Schwab US Dividend Equity ETF trades at $32.82. The key difference: Schwab US Dividend Equity ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | SCHD | |
|---|---|---|
Market Cap | $23.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $81.80 | $33.04 |
52-Week Low | $22.36 | $26.38 |
Enterprise Value | $19.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
SCHD trades at $32.75, down 0.49% today, with technical indicators showing a bullish trend supported by moving averages. The ETF has delivered strong 2026 performance with a 22% year-to-date return and recently surpassed $100 billion in assets under management. Recent news highlights its defensive sector allocation and consistent dividend growth, with a current yield below its historical average due to price appreciation.
The outlook remains positive given SCHD's quality screening methodology and institutional inflows, though risks include interest rate sensitivity and market volatility. Analyst sentiment is bullish with the fund positioned as a defensive income play with capital appreciation potential in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
